Patients
13.4 per 100,000 people
Suicide rate, New Zealand, 2023 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Chandani Patel
New Zealand Psychedelic Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Compound, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$82.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $38.0 Mn | — | — |
| 2025 (base) | $42.8 Mn | +$4.8 Mn | — |
| 2026 (forecast) | $48.2 Mn | +$5.4 Mn | +12.7% |
| 2027 (forecast) | $54.4 Mn | +$6.1 Mn | +27% |
| 2028 (forecast) | $61.3 Mn | +$6.9 Mn | +43.1% |
| 2029 (forecast) | $69.1 Mn | +$7.8 Mn | +61.3% |
| 2030 (forecast) | $77.8 Mn | +$8.8 Mn | +81.8% |
| 2031 (forecast) | $87.7 Mn | +$9.9 Mn | +104.9% |
| 2032 (forecast) | $98.8 Mn | +$11.1 Mn | +130.9% |
| 2033 (forecast) | $111.4 Mn | +$12.6 Mn | +160.3% |
| 2034 (forecast) | $125.5 Mn | +$14.1 Mn | +193.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $42.8 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $125.5 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 12.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Compound, indication and end user (see all) |
| Key players | Compass Pathways, Lykos Therapeutics, MindMed, Cybin, atai Life Sciences (see all) |
| Regulator in New Zealand | MedsafeSource: Medsafe. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Psychedelic therapeutics use compounds such as psilocybin, MDMA and LSD with therapy support to treat depression, PTSD and addiction.
Key segments of the psychedelic Therapeutics market include compound (Psilocybin, MDMA and LSD) and indication (Treatment-Resistant Depression, PTSD and Substance Use Disorder).
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the psychedelic Therapeutics market. Governments and employers are investing more in mental health care.
Digital tools, new drug classes and care built into primary care and workplaces give the psychedelic Therapeutics market strong room to grow worldwide.
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the psychedelic Therapeutics market.
The psychedelic Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medsafe, part of the Ministry of Health, approves medicines before they can be sold.[1] Pharmac decides which medicines and medical devices the public health system pays for.[2] Suicide rate: 13.4 per 100,000 people in 2023, the latest WHO figure for New Zealand.[3]
[1] Medsafe. Checked 14 Nov 2026.
[2] Pharmac. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for psychedelic Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.
What doctors and scientists are doing in Psychedelic Therapeutics right now, from free public sources.
13.4 per 100,000 people
Suicide rate, New Zealand, 2023 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
From our blog
New Zealand
New Zealand
New Zealand
New Zealand
New Zealand
New Zealand
OTC & Nutraceuticals · New Zealand
Digital Health · New Zealand
Digital Health · New Zealand
OTC & Nutraceuticals · New Zealand
Healthcare Services · New Zealand
Healthcare Services · New Zealand